In-House Plasmid Production To Secure Supply Chains

By Kristin Heller, Andrew Moreo, and Jonathan Rush, Andelyn Biosciences


Access to plasmid is a significant stumbling block in downstream biopharmaceutical manufacturing; instability in manufacturing, as well as issues identified post-sequencing, are perhaps bigger factors in this problem than capacity, but each are important considerations for companies looking to streamline their development efforts. Working closely with a CDMO that performs in-house plasmid production affords companies the opportunity to collaborate and optimize processes and create efficiencies.

Partnering with a plasmid supplier that can scale alongside a therapy’s development can save companies time and money through standardized, connected protocols, comprehensive data aggregation, and in-house expertise. Andelyn Biosciences, a pioneering biopharmaceutical CDMO with capabilities that span plasmid production, viral vector analytical development, small- and large-scale adherent and suspension GMP drug substance manufacturing, and finished drug product manufacturing, has invested years of research to optimize its plasmid production capabilities. By prioritizing cross-functional communication and utilizing an enterprise resource planning system supported by frequent demand meetings, Andelyn works to ensure material availability and adequate safety stock.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene